Cost of invasive fungal infections in the era of new diagnostics and expanded treatment options

Pharmacotherapy

Volumn 32, Issue 10, 2012, Pages 890-901

  Ashley, Elizabeth Dodds ^a,b   Drew, Richard ^a,c   Johnson, Melissa ^a,c   Danna, Robert ^d   Dabrowski, Dominika ^e   Walker, Valery ^e   Prasad, Manishi ^f   Alexander, Barbara ^a   Papadopoulos, George ^f   Perfect, John ^a  

^a DUKE UNIVERSITY   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c CAMPBELL UNIVERSITY   (United States)

^d META   (United States)

^e OPTUM   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antifungal; Aspergillosis; Candidiasis; Invasive fungal infection; Pharmacoeconomics

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; VORICONAZOLE;

ADOLESCENT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; COST CONTROL; COST OF ILLNESS; CRYPTOCOCCOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG COST; DRUG EFFICACY; FEMALE; HEALTH CARE UTILIZATION; HOSPITAL PATIENT; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; SENSITIVITY ANALYSIS; SYSTEMIC MYCOSIS; ZYGOMYCOSIS;

ACADEMIC MEDICAL CENTERS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS, INVASIVE; CRYPTOCOCCOSIS; DRUG COSTS; FEMALE; HOSPITAL COSTS; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; NORTH CAROLINA; SEVERITY OF ILLNESS INDEX; YOUNG ADULT; ZYGOMYCOSIS;

EID: 84867316620     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1875-9114.2012.01124     Document Type: Article

References (39)

1. Ellis M. Invasive fungal infections: evolving challenges for diagnosis and therapeutics. Mol Immunol 2002;12-13:947-57.
2. Pappas PG, Rotstein CMF, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007;45:883-93.
3. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347(25):2020-9.
4. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351(14):1391-402.
5. Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006;50(2):658-66.
6. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347(6):408-15.
7. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003;36(9):1122-31.
8. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346(4):225-34.
9. van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004;39 (10):1407-16.
10. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007;356(24):2472-82.
11. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356(4):335-47.
12. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356(4):348-59.
13. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007;44(1):2-12.
14. Wilson LS, Reyes CM, Stolpman M, Speckman J, Allen K, Beney J. The direct cost and incidence of systemic fungal infections. Value Health 2002;5(1):26-34.
15. Dixon S, McKeen E, Tabberer M, Paisley S. Economic evaluations of treatments for systemic fungal infections: a systematic review of the literature. Pharmacoeconomics 2004;22(7):421-33.
16. Rapp RP. Changing strategies for the management of invasive fungal infections. Pharmacotherapy 2004;24(2):4S-28S.
17. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005;41(9):1232-9.
18. Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998;27(4):781-8.
19. Morgan J, Meltzer MI, Plikaytis BD, et al. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005;26(6):540-7.
20. Dasbach EJ, Davies GM, Teutsch SM. Burden of aspergillosisrelated hospitalizations in the United States. Clin Infect Dis 2000;31(6):1524-8.
21. Cagatay AA, Cosan F, Karadeniz A, et al. The clinical and pharmacoeconomic analysis of invasive aspergillosis in adult patients with haematological diseases. Mycoses 2008;51(4): 328-35.
22. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106(10): 2258-66.
23. Tong KB, Lau CJ, Murtagh K, Layton AJ, Seifeldin R. The economic impact of aspergillosis: analysis of hospital expenditures across patient subgroups. Int J Infect Dis 2009;13(1):24-36.
24. Wenzel R, Del Favero A, Kibbler C, et al. Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients. J Antimicrob Chemother 2005;55(3):352-61.
25. Lewis JS, Boucher HW, Lubowski TJ, Ambegaonkar AJ, Day DL, Patterson TF. Cost advantage of voriconazole over amphotericin B deoxycholate for primary treatment of invasive aspergillosis. Pharmacotherapy 2005;25(6):839-46.
26. Bates DW, Su L, Yu DT, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001;32(5):686-93.
27. Garey KW, Neuhauser MM, Bearden DT, et al. Evaluation of antifungals in the surgical intensive care unit: a multi-institutional study. Mycoses 2006;49(3):226-31.
28. De Vries R, Daenen S, Tolley K, et al. Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections. Pharmacoeconomics 2008;26(1):75-90.
29. Cornely OA, Sidhu M, Odeyemi I, van Engen AK, van der Waal JM, Schoeman O. Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany. Curr Med Res Opin 2008;24(6):1743-53.
30. Selleslag D, Vogelaers D, Marbaix S. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Belgium. Acta Clin Belg 2009;64(5): 393-8.
31. de Pauw B, Walsh T, Donnelly JP, et al. EORTC/MSG consensus revised definitions draft VI. Doctor Fungus Web site, 2005. Availiable from http://www.doctorfungus.org/lecture/EORTC-MSG-rev06.htm. Accessed April 9, 2010.
32. Institute for Health and Socio-Economic Policy. IHSP hospital 200: hospitals, big pharma, HMOs and the health care war economy. Orinda, CA: IHSP, 2004.
33. Menzin J, Lang KM, Friedman M, Dixon D, Marton JP, Wilson J. Excess mortality, length of stay, and costs associated with serious fungal infections among elderly cancer patients: findings from linked SEER-Medicare data. Value Health 2005;8(2):140-8.
34. Menzin J, Meyers JL, Friedman M, et al. Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients. Am J Health Syst Pharm 2009;66 (19):1711-7.
35. Sidhu MK, van Engen AK, Kleintjens J, Schoeman O, Palazzo M. Cost-effectiveness analysis of micafungin versus caspofungin for treatment of systemic Candida infections in the UK. Curr Med Res Opin 2009;25(8):2049-59.
36. O'Sullivan AK, Pandya A, Papadopoulos G, et al. Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States. Value Health 2009;12(5):666-73.
37. Al-Badriyeh D, Liew D, Stewart K, Kong DC. Cost-effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia. J Antimicrob Chemother 2009;63(1):197-208.
38. Al-Badriyeh D, Slavin M, Liew D, et al. Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia. J Antimicrob Chemother 2010;65(5):1052-61.
39. Zilberberg MD, Kothari S, Shorr AF. Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation. Crit Care 2009;13(3):R94.